We are developing the first mRNA nanoparticle vaccines with advanced computational analysis and deep learning AI systems. Our mRNA vaccines directly encoding for highly immunogenic nanoparticles provide a flexible platform applicable to many pathogens.
Our SARS-CoV-2 vaccine is designed to complement the limited immunity provided by first and second generation COVID vaccines, and to protect against the latest LP.8.1 variant now prevalent worldwide. Our SARS-CoV-2 vaccine is also designed to counter immune imprinting which results from all COVID vaccines to date and limits their efficacy.
Our Nipah virus vaccine is the first mRNA nanoparticle vaccine against the Nipah virus causing the recent outbreaks in India and South Asia with very high fatality rates.
A critical advantage of our mRNA nanoparticle vaccines is to induce long-lasting immunity as compared with current mRNA vaccines. They are also designed to protect against viral dissemination and the associated neurological symptoms, such as long COVID syndrome and Nipah encephalitis.